StockData
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO) stock

INONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$1.69+0.06 (+3.68%)

Close on Nov 18, 2026Market cap $174.74MP/E –Yield –

Inovio Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Inovio Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $65.34K, down 70.0% from the year before. Over ten years it grew -47.4% a year on average. The highest annual figure on record is $42.22M in fiscal 2017.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$65.34K-70.0%
FY2024Dec 31, 2024$217.76K-73.8%
FY2023Dec 31, 2023$832.01K-91.9%
FY2022Dec 31, 2022$10.26M+478.2%
FY2021Dec 31, 2021$1.77M-76.1%
FY2020Dec 31, 2020$7.41M+80.2%
FY2019Dec 31, 2019$4.11M-86.5%
FY2018Dec 31, 2018$30.48M-27.8%
FY2017Dec 31, 2017$42.22M+19.4%
FY2016Dec 31, 2016$35.37M-12.8%
FY2015Dec 31, 2015$40.57M+288.0%
FY2014Dec 31, 2014$10.46M-22.4%
FY2013Dec 31, 2013$13.47M+227.0%
FY2012Dec 31, 2012$4.12M-58.0%
FY2011Dec 31, 2011$9.80M+59.4%
FY2010Dec 31, 2010$6.14M-32.6%
FY2009Dec 31, 2009$9.12M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$65.34K–
Q4 FY2024Dec 31, 2024$116.99K+14.0%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$100.76K-55.4%
Q1 FY2024Mar 31, 2024$0-100.0%
Q4 FY2023Dec 31, 2023$102.65K-17.7%
Q3 FY2023Sep 30, 2023$388.45K-95.8%
Q2 FY2023Jun 30, 2023$225.97K-71.2%
Q1 FY2023Mar 31, 2023$114.94K-42.3%
Q4 FY2022Dec 31, 2022$124.67K-85.1%
Q3 FY2022Sep 30, 2022$9.15M+3038.2%
Q2 FY2022Jun 30, 2022$784.40K+187.5%
Q1 FY2022Mar 31, 2022$199.07K-46.4%
Q4 FY2021Dec 31, 2021$839.12K-85.0%
Q3 FY2021Sep 30, 2021$291.70K+23.5%
Q2 FY2021Jun 30, 2021$272.82K+2.1%
Q1 FY2021Mar 31, 2021$371.12K-72.0%
Q4 FY2020Dec 31, 2020$5.58M+1896.7%
Q3 FY2020Sep 30, 2020$236.18K-72.8%
Q2 FY2020Jun 30, 2020$267.19K+96.9%
Q1 FY2020Mar 31, 2020$1.33M-53.1%
Q4 FY2019Dec 31, 2019$279.49K-88.8%
Q3 FY2019Sep 30, 2019$866.86K-56.7%
Q2 FY2019Jun 30, 2019$135.67K-99.4%
Q1 FY2019Mar 31, 2019$2.83M+85.0%
Q4 FY2018Dec 31, 2018$2.50M-71.5%
Q3 FY2018Sep 30, 2018$2.00M-24.3%
Q2 FY2018Jun 30, 2018$24.45M+19.8%
Q1 FY2018Mar 31, 2018$1.53M-85.3%
Q4 FY2017Dec 31, 2017$8.79M+3.2%
Q3 FY2017Sep 30, 2017$2.64M-78.9%
Q2 FY2017Jun 30, 2017$20.41M–
Q1 FY2017Mar 31, 2017$10.38M–
Q4 FY2016Dec 31, 2016$8.51M–
Q3 FY2016Sep 30, 2016$12.54M–

More Inovio Pharmaceuticals figures

See a number that looks wrong?